Antibiotic Concentrations Among Critically Ill Patients (DALI)

Centre Hospitalier Universitaire de Nīmes

Status: Completed

Conditions: Administration of Antibiotics in Intensive Care Units

Treatments: Biological: Blood sampling

Study type: Observational

Funder types: Other

Identifiers

NCT01543334

LOCAL/2011/JYL-03

2011-A01339-32 (Other Identifier)

Details and patient eligibility

About

The primary objective of the DALI study is to compare antibiotic concentrations in patient blood samples with bacteriological objectives associated with maximum bactericidal activity. The antibiotics studied are certain lactams and glycopeptides.

Enrollment: 98 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• The patient (or his/her "trusted representative") must have given his/her informed and signed consent
• Antibiotic treatment is administered with beta-lactams or glycopeptides administered continuously or intermittently (Can be of the following: Amoxicillin-clavulanic acid, ampicillin, piperacillin-tazobactam, penicillin G, flucloxacillin, dicloxacillin, cloxacillin, cefazolin, ceftazidime, ceftriaxone, cefepime, meropenem, imipenem, doripenem, ertapenem; Vancomycin, teicoplanin).
• A vein or artery catheter is established to facilitate blood sampling (arterial catheter is preferred)

Exclusion criteria

• None of the above-mentioned antibiotics are administered
• Impossible to establish venous or arterial catheter
• Consent not given
• Patient is pregnant, parturient or breastfeeding
• The patient is under tutorship or curatorship
• The patient is participating in another study

Trial design

98 participants in 1 patient group

Patients

Description:

Patients with a vein or artery catheter and who are being administered antibiotics. The latter can be of the following: Amoxicillin-clavulanic acid, ampicillin, piperacillin-tazobactam, penicillin G, flucloxacillin, dicloxacillin, cloxacillin, cefazolin, ceftazidime, ceftriaxone, cefepime, meropenem, imipenem, doripenem, ertapenem; Vancomycin, teicoplanin. (see inclusion/exclusion criteria).

Treatment:

Biological: Blood sampling